Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06331312
Registration number
NCT06331312
Ethics application status
Date submitted
20/03/2024
Date registered
26/03/2024
Date last updated
29/06/2025
Titles & IDs
Public title
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Query!
Scientific title
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR)
Query!
Secondary ID [1]
0
0
2023-508077-85-00
Query!
Secondary ID [2]
0
0
CAIN457C22301E1
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
REPLENISH-EXT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Polymyalgia Rheumatica
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Other muscular and skeletal disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Neurological
0
0
0
0
Query!
Other neurological disorders
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Other - Secukinumab
Experimental: Secukinumab 300mg - All eligible participants will receive secukinumab 300 mg s.c. (2 x 150mg/1mL PFS secukinumab) from baseline and every 4 weeks up to 2 years. The study medication may be modified/adjusted after the initial doses of 300mg s.c. (decreased to 150mg s.c. q4w or increased again from 150mg s.c. q4w to 300mg s.c. q4w) if deemed appropriate by the investigator. Dose modification/adjustment may only occur from Week 24 visit onwards. The modification/adjustment of the study medication will be determined at a site visit.
Treatment: Other: Secukinumab
2 x 150mg/1mL PFS secukinumab
Query!
Intervention code [1]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Incidences of treatment emergent adverse events (AEs) and serious adverse events (SAEs)
Query!
Assessment method [1]
0
0
The number and percentage of participants with treatment emergent AEs/SAEs will be summarized. No hypothesis testing will be performed.
Query!
Timepoint [1]
0
0
After the first dose of study treatment and within 84 days after the last dose
Query!
Eligibility
Key inclusion criteria
* Participants who have completed 52-week Treatment Period as per protocol in a Novartis study of secukinumab in PMR patients (the "core study" - Study CAIN457C22301), AND
* who have experienced a relapse during the treatment-free follow-up period of the core study, AND
* who have not been on rescue treatment.
* The participant would potentially derive benefit from secukinumab, and the benefit outweighs the risk, based on the investigator's judgement.
Query!
Minimum age
50
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Use of prohibited medications, as specified in the protocol
* History of ongoing, chronic or recurrent infectious disease (i.e., human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), active tuberculosis infection (TB))
* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
* Live vaccinations (e.g., monkey pox vaccine, oral polio vaccine, varicella/zoster vaccines) within 6 weeks prior to Baseline
* Subjects whose participation in the extension study could expose them to an undue safety risk
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Not applicable
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/06/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
10/02/2028
Query!
Actual
Query!
Sample size
Target
300
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD,VIC
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Southport
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Heidelberg Heights
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Parramatta
Query!
Recruitment postcode(s) [1]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [2]
0
0
3081 - Heidelberg Heights
Query!
Recruitment postcode(s) [3]
0
0
2150 - Parramatta
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Michigan
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Hampshire
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
Argentina
Query!
State/province [10]
0
0
Buenos Aires
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
SP
Query!
Country [12]
0
0
Canada
Query!
State/province [12]
0
0
Quebec
Query!
Country [13]
0
0
Chile
Query!
State/province [13]
0
0
RM
Query!
Country [14]
0
0
Chile
Query!
State/province [14]
0
0
Valparaiso
Query!
Country [15]
0
0
Chile
Query!
State/province [15]
0
0
Santiago
Query!
Country [16]
0
0
Colombia
Query!
State/province [16]
0
0
Atlantico
Query!
Country [17]
0
0
Colombia
Query!
State/province [17]
0
0
Bogota
Query!
Country [18]
0
0
Czechia
Query!
State/province [18]
0
0
Czech Republic
Query!
Country [19]
0
0
Czechia
Query!
State/province [19]
0
0
Brno
Query!
Country [20]
0
0
Czechia
Query!
State/province [20]
0
0
Hlucin
Query!
Country [21]
0
0
Czechia
Query!
State/province [21]
0
0
Praha 2
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Praha 4
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Uherske Hradiste
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Zlin
Query!
Country [25]
0
0
Denmark
Query!
State/province [25]
0
0
Gandrup
Query!
Country [26]
0
0
Denmark
Query!
State/province [26]
0
0
Vejle
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Val De Marne
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Brest
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Cholet
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Colmar Cedex
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Dijon
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Le Mans
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Montpellier 5
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Nantes
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Reims
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Strasbourg
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Toulouse
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Berlin
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Dresden
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Freiburg
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Herne
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Ratingen
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Rendsburg
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Budapest
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Szeged
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Veszprem
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
MI
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
PG
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
PV
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
RE
Query!
Country [51]
0
0
Japan
Query!
State/province [51]
0
0
Fukuoka
Query!
Country [52]
0
0
Japan
Query!
State/province [52]
0
0
Hokkaido
Query!
Country [53]
0
0
Japan
Query!
State/province [53]
0
0
Kanagawa
Query!
Country [54]
0
0
Japan
Query!
State/province [54]
0
0
Nagano
Query!
Country [55]
0
0
Japan
Query!
State/province [55]
0
0
Osaka
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Tokyo
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Yamaguchi
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Yamanashi
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Okayama
Query!
Country [60]
0
0
Lebanon
Query!
State/province [60]
0
0
Ashrafieh
Query!
Country [61]
0
0
Mexico
Query!
State/province [61]
0
0
Jalisco
Query!
Country [62]
0
0
Netherlands
Query!
State/province [62]
0
0
Almelo
Query!
Country [63]
0
0
Netherlands
Query!
State/province [63]
0
0
Groningen
Query!
Country [64]
0
0
Netherlands
Query!
State/province [64]
0
0
Rotterdam
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Bytom
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Lublin
Query!
Country [67]
0
0
Poland
Query!
State/province [67]
0
0
Warszawa
Query!
Country [68]
0
0
South Africa
Query!
State/province [68]
0
0
Cape Town
Query!
Country [69]
0
0
South Africa
Query!
State/province [69]
0
0
Panorama
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Andalucia
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Barcelona
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Comunidad Valenciana
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Galicia
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Pais Vasco
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Madrid
Query!
Country [76]
0
0
Switzerland
Query!
State/province [76]
0
0
Basel
Query!
Country [77]
0
0
Switzerland
Query!
State/province [77]
0
0
St Gallen
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Hull
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06331312
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-888-669-6682
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06331312
Download to PDF